Using competence network collaboration and decision-analytic modeling to assess the cost-effectiveness of interferon α-2b plus ribavirin as initial treatment of chronic hepatitis C in Germany
- 1 June 2005
- journal article
- Published by Springer Nature in The European Journal of Health Economics
- Vol. 6 (2) , 112-123
Abstract
The objective of this study was to translate and apply a decision-analytic model for chronic hepatitis C (CHC) to the German health care context using competence network collaboration. The German Hepatitis C Model (GEHMO) competence network used a systematic multistep approach to identify and transfer a high quality Markov model for CHC to the German health care context. GEHMO was used to project lifetime clinical and economic outcomes and to determine the cost-effectiveness of initial antiviral therapy with interferon α-2b plus ribavirin from a societal perspective. In 40-year-old patients combination therapy for 24 and 48 weeks increased life expectancy by 1.6 and 2.3 years, respectively, compared with interferon alone for 48 weeks. The discounted incremental cost-utility ratios (ICUR) for combination therapy were €5,500 per quality-adjusted life-year gained (QALY) for 24 weeks and €6,800/QALY for 48 weeks of treatment. ICUR was €9,800/QALY for moving from 24 to 48 weeks of treatment. Combination therapy remained cost-effective in sensitivity analyses. In conclusion, combination therapy with interferon α-2b and ribavirin is effective and cost-effective compared with other well-accepted medical treatments. Competence network collaboration and decision modeling provide a useful and efficient approach to combine evidence from international studies with country-specific parameters.Keywords
This publication has 64 references indexed in Scilit:
- When should decision-analytic modeling be used in the economic evaluation of health care?The European Journal of Health Economics, 2003
- The Prevalence of Hepatitis C Virus Infection in the United States, 1988 through 1994New England Journal of Medicine, 1999
- EASL International Consensus Conference on Hepatitis C Paris, 26–28 February 1999Journal of Hepatology, 1999
- EASL International Consensus Conference on Hepatitis CParis, 26–27 February 1999Consensus StatementJournal of Hepatology, 1999
- Chronic hepatitis C virus infection causes a significant reduction in quality of life in the absence of cirrhosisHepatology, 1998
- Health assessment for chronic HCV infectionDigestive Diseases and Sciences, 1996
- Genetic predispositions for immunological features in chronic liver diseases other than autoimmune hepatitisJournal of Hepatology, 1996
- Long-term follow-up of non-A, non-B (type C) post-transfusion hepatitisJournal of Hepatology, 1992
- Long-term follow-up of posttransfusion and sporadic chronic hepatitis non-A, non-B and frequency of circulating antibodies to hepatitis C virus (HCV)Journal of Hepatology, 1990
- Formulation and application of a numerical scoring system for assessing histological activity in asymptomatic chronic active hepatitis†Hepatology, 1981